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Abstract: 
The aims were to determine the biodistribution, translocation, and persistence of nanoceria in 
the brain and selected peripheral organs. Nanoceria is being studied as an anti-oxidant 
therapeutic. Five, 15, 30, or 55 nm ceria was iv infused into rats which were terminated 1, 20, 
or 720 h later. Cerium was determined in blood, brain, liver, and spleen. Liver and spleen 
contained a large percentage of the dose, from which there was no significant clearance over 
720 h, associated with adverse changes. Very little nanoceria entered brain parenchyma. The 
results suggest brain delivery of nanoceria will be a challenge.   
Introduction: 
Nanotechnology has the potential to revolutionize drug delivery and manufactured products, 
leading to greater human engineered nanomaterial (ENM) exposure. This requires 
understanding of ENM pharmacokinetics and toxicity.  Ceria (a.k.a.: CeO2, cerium oxide) 
ENMs have current commercial uses and potential medical applications. Major industrial uses 
are as a diesel fuel additive to catalyze combustion and decrease combustion temperature and 
in chemical-mechanical planarization (integrated circuit manufacture) 1. Ceria ENMs are 
expected to have future application in fuel cells and batteries.  Ceria redox activity creates the 
potential to reduce reactive oxygen and nitrogen species (ROS and RNS)-induced disorders, 
providing potential as a therapeutic agent. This has been demonstrated in numerous studies in 
which oxidative stress was induced (Table 1). On the other hand, studies have demonstrated 
that nanoceria redox activity can increase oxidative stress, the major untoward effect of ENMs 
(Table 1). However, these studies do not inform about ceria ENM distribution in animals, or its 
ability to enter the brain.  
 
The extent of ceria ENM uptake from the gastrointestinal tract is very low, producing very small 
increases in organ cerium. Ceria was detected in lung and spleen, but not brain, heart, kidney, 
or liver of mice after 5 weekly oral doses of a 3 to 5 nm ceria (0.5 mg/kg; 2900 nmol/kg) 2. 1 
Oral administration of a 7 nm ceria (~ 5 mg/kg; 29,000 nmol/kg), resulted in ~ 1 x 10-4 % of the 
dose in the liver and ~ 1 x 10-6 to 1 x 10-5 % in the brain, heart, kidney, lung, spleen, and 
testicle 1 to 7 days later 3. Single oral administration of 30 nm ceria (0.1 g/kg; 580,000 
                                                          
1 :  Doses of ceria ENMs, reported or used in this work as mass ceria ENM/body weight, are also expressed in ceria ENM molarity, to facilitate 
comparison among studies, particularly in vitro to in vivo. 
nmol/kg) resulted in ~ 2 to 4 x 10-3 % of the dose in the brain, kidney, liver, lung, spleen, and 
testicle 1 to 14 days later, and after a larger dose (5 g/kg; 29,000,000 nmol/kg) proportionally 
more in the lung than other sampled organs (~5 to 35 x 10-4 % of the dose) 4. Uptake of 7 nm 
ceria (0.2 mg; 1160 nmol) from the lung resulted in translocation into the central compartment 
(blood) and organs, including ~1 x 10-5, 1 x 10-4, 1 x 10-3, 1 x 10-2, and 1 x 10-1 % of the dose in 
the brain, heart and testicle, kidney, spleen, and liver, respectively, 28 days later 3. Although 
cerium was detected in the brain after ceria ENM oral administration, intratracheal instillation 
and inhalation 3-5, its distribution into brain parenchyma was not reported. These results 
suggest the therapeutic use of ceria ENM for brain disorders might require a route of 
administration other than oral or inhalation. 
 
Intravenous injection of 3 to 5 nm ceria (0.1 or 0.5 mg/kg; 580 or 2900 nmol/kg) on Days 1 and 
15 resulted in 100 to 200 nm electron-dense cerium-suspect granules in hepatocytes and renal 
tubular cells on Day 30. Cerium in other tissues was not reported 6. A previous study showed 
considerable 30 nm commercial (platelet shaped) ceria retention in the liver and spleen, with 
much less  in the brain, 1 and 20 h after iv administration of 50 to 750 mg/kg (290,000 to 
4,350,000 nmol/kg) 7. Similarly, liver and spleen contained much more 30 nm ceria ENM up to 
90 days after an 85 mg/kg (495,000 nmol/kg) iv dose 8. Cerium was not detected in brain 1 
week after 5 weekly 2910 nmol/kg 3 to 5 nm ceria iv or ip administrations 2. There is little 
known about the effects of ceria ENM size on its distribution in the mammal. The need for in 
vivo studies that examine the biokinetics and toxicity of ceria ENMs was identified 1. For ceria 
ENM to be used as a therapeutic agent to treat neurodegenerative diseases, it presumably 
needs to enter the central nervous system.   
 
The objectives of the present research were to ascertain the effect of ENM size on distribution 
into selected organs, including the brain and ENM translocation up to 30 days (720 h) after a 
single iv ceria ENM infusion. This study addresses the longer term fate of the 4 sizes of citrate-
coated ceria ENMs we studied for their distribution within, and elimination from, blood 9, 
focusing on their distribution and persistence in the brain, liver and spleen.  
Methods:  
The ceria ENMs studied: 
Five, 15, 30, and 55 nm nominal diameter citrate-capped ceria ENMs were synthesized and 
extensively characterized in house. Synthesis and characterization methods and results are 
described in the Supplemental Information.  Based on preliminary studies described in the 
Supplemental Information, target doses were 100 mg ceria ENM/kg for the 5, 15, and 30 nm 
ceria, and 50 mg/kg for the 55 nm ceria ENM. Based on cerium analysis in representative 
aliquots of the dosing material, the delivered doses were 85, 70, 85, and 50 mg/kg (495,000, 
410,000, 495,000, and 290,000 nmol/kg) for the 5, 15, 30, and 55 nm ceria, respectively. This 
large ceria exposure was utilized to enhance our ability to detect cerium in the blood and 
organs up to 30 days after the single ceria ENM infusion.  
 
Animals: 
This study reports results from 126 male Sprague Dawley rats, weighing 333 ± 35 g (mean ± 
SD) (~ 75 days old). Procedures to prepare the rats for iv ceria ENM infusion, preliminary 
studies to identify the ceria ENM dose for this work, methods to determine blood-brain barrier 
(BBB) integrity, organ and blood collection and processing procedures, cerum quantification 
methods, and light and electron microscopic assessment methods are described in the 
Supplemental Information.  The rats were obtained from Harlan, Indianapolis, IN. They were 
housed individually prior to study and after cannulae removal (a few days after the iv infusion) 
in the University of Kentucky Division of Laboratory Animal Resources facility under a 12:12 h 
light:dark cycle at 70 ± 8°F and 30 to 70% humidity. The rats had free access to 2018 Harlan 
diet and reverse osmosis water. Animal work was approved by the University of Kentucky 
Institutional Animal Care and Use Committee. The research was conducted in accordance with 
the Guiding Principles in the Use of Animals in Toxicology 
(http://www.toxicology.org/ai/air/air6.asp). 
 
Data and statistical analysis: 
Cerium concentrations below the method detection limit (MDL) were assigned 50% of the MDL 
and included in the statistical analysis as such.  The percentage of the ceria ENM dose in the 
brain, liver, and spleen was calculated as cerium concentration times organ weight divided by 
the ceria ENM dose, which was based on cerium quantification in the dosing dispersion 
(determined by inductively coupled plasma mass spectrometry (ICP-MS)) times the dose 
volume. The percentage of the ceria dose in blood was based on a vascular volume of 7% of 
the rat’s body weight (http://oacu.od.nih.gov/ARAC/Bleeding.pdf). Outliers in blood and tissue 
cerium concentration results identified by the Grubb’s test 
(http://www.graphpad.com/quickcalcs/Grubbs1.cfm) were not used in data analysis.  
 
Statistical comparison of % of the ceria ENM dose in blood, brain, liver, and spleen of the 
control rats for each of the 4 treatment (ceria ENM size) groups was conducted using one-way 
ANOVA followed by Tukey’s post-hoc test and found to not be significant. Results of all control 
rats for blood and each organ were merged and compared to the % of the ceria ENM dose in 
treated rats by Dunnett’s test; and within blood or an organ across termination times for each 
of the 4 ceria ENMs by ANOVA with Tukey’s post-hoc test or two-tailed unpaired t tests. 
Comparison of the % of the ceria ENM dose in blood or an organ at the same time following 
infusion of the 4 ceria ENM sizes was conducted using one-way ANOVAs followed by Tukey’s 
post-hoc tests.  Results from control and treated rats were compared for brain BBB marker 
concentration by one-tailed unpaired t tests. Significance was accepted at p < 0.05, except for 
the mass amount of cerium in the blood or organs as a percentage of the ceria dose, for which 
alpha was adjusted to 0.05/10 to correct for the multiple comparisons. Results are reported as 
mean ± S.D. 
Results:  
Characterization of nanomaterials should include composition, morphology (average primary 
particle size and distribution, shape, and structure), surface properties (charge, coatings), and 
agglomeration in relevant media. Table 2 and Figures 1 and 2 show this information for the 
ceria ENMs studied. All samples were crystalline (X-ray diffraction, confirmed by TEM). TEM 
verified that the primary particles were distinct and not aggregated. 
 
The primary particle sizes were determined by counting 50 to 100 particles in TEM images and 
using a lognormal function to model the number-based cumulative particle size distribution, 
reported as Average Primary Particle Size: TEM in Table 2. Cumulative data and model 
distributions are shown in Figure 1A. The probability density functions (computed from the 
lognormal models; Figure 1B) show that the 5, 15, and 55 nm materials were mutually 
exclusive with respect to primary particle size, whereas the 30 nm ceria had significant 
overlaps with the 15 and the 55 nm ENMs. 
 
Specific surface area measurements can be used as confirmation of primary particle size. 
Results of BET surface determination for the 5, 15, and 30 nm ceria ENMs are shown in Table 
2, and were converted to average primary particle size (square brackets). In general, there is 
good agreement between the primary particle size averages determined by TEM and surface 
area. The number-based primary particle size distribution was used to compute the Sauter 
mean diameter (d32), a surface area-based average (curly brackets under the TEM data), 
which corresponded well with the BET-determined average particle sizes. High surface area 
relative to that expected from the primary particle size might identify internal porosity. None of 
these materials appears to have internal porosity, consistent with their crystal morphology. 
 
All ceria ENMs had surface citrate to aid aqueous media dispersion and reduce agglomeration 
(Table 2). All of these ENMs were expected to form stable dispersions in water (zeta potentials 
were < -30 mV) (Table 2). Figure 2 shows number- and volume-based particle size 
distributions for the ceria ENMs in water, measured using dynamic light scattering and 
evaluated using the multimodal feature, which helps identify fractions with different particle 
sizes. The number-based distributions are monomodal, but all are somewhat larger than those 
generated from TEM measurements, suggesting possible nanoparticle agglomeration in water. 
Volume-based distributions in Figure 2 correspond to the conditions in the dose solution; most 
of the nanoceria mass will be associated with larger structures. These volume-based 
distributions show the presence of agglomerates much larger than the primary nanoparticles. 
In general, there can be a dynamic equilibrium between the agglomerates and primary 
nanoparticles in water. Therefore, agglomeration would not necessarily prevent movement of 
nanoceria across biological barriers, but it could reduce the rate. 
 
Necropsy observation of the rats that received the 55 nm ceria ENM revealed a white deposit 
in the vena cava at the tip of the cannula that infused the ceria, indicating that a significant 
amount of ceria was deposited there during its infusion, and did not circulate in the blood. This 
was presumably due to the presence of the larger sized particles in this ENM and its lower 
extent of surface citrate coating.  
 
Of the 216 samples from control rats analyzed for cerium, 47 were above the MDL of 0.089 
mg/kg for tissue and 0.018 mg/l for blood. Ten were outliers by the Grubb’s test. Of the 278 
samples from ceria ENM treated-rats analyzed for cerium, all but 27 were above the MDL; 7 
were blood samples from rats 30 days after the 30 or 55 nm ENMs and 20 were brain 
samples. Samples having less than the MDL value in ENM-treated rats reflect the low cerium 
concentration in blood 30 days after ceria ENM administration and in brain at all times. This 
can be seen in Figure 3 which shows the percentage of the ceria dose in blood, brain, liver, or 
spleen after ceria ENM treatment. For all of the control rats, the mean amount of cerium in 
blood, brain, liver, and spleen, expressed as a % of the ceria dose given to the treated rats, 
was 0.003, 0.001, 0.0004 and 0.04, respectively. Figure 3 also shows significant differences of 
the ceria dose in blood or organs between times after a ceria ENM administration. There were 
no significant decreases of Ce in the liver or spleen over time. To the contrary, the percentage 
of the ceria dose in the spleen significantly increased over time after administration of the 15 
and 30 nm ceria.  The sum of the percentages of the ceria dose in the blood and 3 organs 
sampled accounted for 53 to 62%, 36 to 38%, 41 to 45%, and 13 to 24% of the 5, 15, 30, and 
55 nm ceria ENM doses, respectively. As appreciable fecal and urinary cerium ENM excretion 
were not seen 2, 8, the remainder of the dose was evidently in un-sampled sites.   
 
There was a significantly greater % of the 5 nm ceria dose in blood 1 and 20 h after infusion 
than the other 3 ceria ENM sizes. Brain had a significantly greater % of the 5 nm ceria dose 
than the 30 nm ceria at all times. The % of the 55 nm ceria dose was less in brain, spleen, and 
liver 20 h after infusion than after the smaller sized ceria ENMs. The spleen contained 
significantly less of the total dose of the 5 nm than the 15 nm ceria at 15 days, whereas the 
liver contained more of the 5 than 30 nm ceria at 20 h.   
 
Brain fluorescein was greater in all ceria-treated compared to control rats except for the rats 
that received 5 nm ceria 20 h after dosing, but only reached statistical significance in rats that 
received 30 nm ceria evaluated 20 h after dosing. Brain horseradish peroxidase was greater in 
all ceria-treated compared to control rats except for those that received the 55 nm ceria and 
were evaluated after 20 h, but only approached statistical significance (p = 0.06) for the rats 
the received 5 nm ceria and were evaluated after 20 h.  
 
In addition, many ceria-treated rats that received the 5 or 30 nm ENM showed punctate white 
specs on the spleen surface 30 days after ceria infusion that appeared to be similar to deposits 
observed in the vena cava at the infusion site and were found to be ceria agglomerations.  Two 
peripheral organs rich in reticuloendothelial cells, the liver and spleen, showed a large 
retention of nanoceria. Intra-sinusoidal cell aggregates were formed by ceria-containing 
Kupffer cells and adherent mononucleated cells. Ultrastructural study demonstrated ceria 
uptake and retention in Kupffer cells with most of the internalized ceria as agglomerates 
(Figure 4A). Agglomeration of cytoplasmic nanoceria in the spleen appeared similar to the liver 
(Figure 4B). Considerable effort to detect nanoceria in hippocampus and cerebellum in 5 and 
30 nm ceria-infused rats revealed only very rare electron dense particulates.  
 
The results of more extensive investigation of ceria ENM localization, histological changes, 
and valence in the liver of these rats 30 days after 5 nm ceria administration were reported 10. 
Intracellular ceria ENM agglomerates were seen in the cytoplasm of Kupffer cells, stellate 
cells, and hepatocytes that were usually membrane bound but not found within mitochondria or 
the cell nucleus. Electron energy loss spectrometry showed the ceria ENM had significant 
oxygen vacancies in the as-synthesized powder with little change after 30 days in situ in the 
liver 8.   
Discussion:  
Measurements of primary particle size (the smallest identifiable subdivision of the ENM), 
agglomerates, and aggregates are important to interpret the biological responses to ENM 
dosing. The distinction between agglomeration (in a suspension held together by physical 
[e.g., van der Waals or hydrophobic] or electrostatic forces) and aggregation (a cohesive mass 
consisting of particle subunits) is based on a NIST report 11. TEM was the fundamental method 
for determining primary particle size and evaluating particle shape. High-resolution (scanning) 
TEM images of the 4 ceria ENMs showed none of the samples were aggregated 9. The 
average primary particle diameters from the TEM analysis relate reasonably well to the BET 
surface area data (Table 2). Although not spherical, the hydrodynamic diameter of the ceria 
ENMs in the present study was only slightly larger than the TEM geometric diameter, as 
expected given the presence of citrate on the surface, which is expected to add < 1 nm to ENM 
diameter 12.  
 
We reported that the 15, 30, and 55 nm ceria ENMs investigated in the present study were 
rapidly cleared from blood 9. This is supported by the significantly greater % of the 5 nm ceria 
dose in blood 1 and 20 h after its infusion compared to ceria in blood taken after the same 
elapsed times from rats that received the 3 larger ceria ENMs. The longer persistence of the 5 
nm ceria ENM in blood may relate to its greater extent of citrate coating and/or its small size 
avoiding ready recognition by reticuloendothelial organs. The greater % of the 5 nm ceria dose 
in the brain than the 30 nm size at all times may relate to the greater % of the 5 nm ceria dose 
in the blood than the 30 nm size at all times. The rats in this work were not perfused to remove 
blood from their organs when terminated; therefore some of the brain cerium can be attributed 
to cerium in the blood in the vessels in the brain.  Based on the rat brain vascular volume (2% 
of the frontal cortex and 2.6% of gray matter) 13 and cerium concentration in blood determined 
in this study, the cerium in the brain of ceria-ENM treated rats can be accounted for by the 
cerium in circulating blood only in rats terminated 1 h after dosing with the 5 and 30 nm ceria. 
This suggests some ceria ENM associated with the brain microvascular endothelial cells that 
present the first, and major, component of the BBB; pericytes; or astrocyte foot processes that 
comprise the BBB; or penetrated beyond those cells into brain parenchyma. Studies using the 
in situ brain perfusion method 14 with a 2 min perfusion and a procedure to prepare a brain 
capillary poor fraction of brain parenchyma 15 showed all of the 5 nm ceria to be in the brain 
parenchyma-poor fraction, suggesting it had not penetrated the BBB.  Electron microscopy 
showed dense particles, presumably ceria ENM, lining the luminal side of brain microvascular 
endothelial cells, but none in brain parenchyma 16. Extensive EM attempts to visualize the 5 
and 30 nm ceria in the brain 1 h after its infusion provided little concrete evidence of ceria ENM 
in brain parenchyma. The % of the dose of the 55 nm ceria was less in brain, spleen, and liver 
20 h after infusion than after the smaller sized ceria ENMs. This is probably due to the 
accumulation of this largest, least citrate-surface stabilized ceria ENM at the site of its delivery 
into the vena cava, as visually observed.  
 
The present results show considerable uptake by reticuloendothelial organs within 1 h, with 
further uptake over the following ~ 20 h, and no significant reduction over the subsequent 30 
days. The liver contained significantly more of the total dose of the 5 than 30 nm ceria at 20 h 
and the spleen contained significantly more of the 15 nm than the 5 nm ceria at 30 days, 
suggesting preferential clearance of smaller particles by the liver component of the 
mononuclear phagocyte system. Cerium concentration in healthy adult Chinese men who 
suffered sudden death was 100-fold higher in the liver than blood and intermediate in 16 other 
tissues, expect for lung, which was higher than liver. Compared to liver cerium concentration, 
spleen cerium was generally higher after ceria ENM in the present study, whereas in human 
spleen cerium was ~ 5% of the liver cerium concentration, showing considerable difference 
between cerium retention from normal exposures and ENMs.  Brain cerium was not 
determined in the human study 17. The mean mass amount of cerium in the blood, liver, and 
spleen of ceria-treated rats among the 10 treatment groups of the present study ranged from 
1.3 to 9044-fold, 1410 to 34470-fold, and 280 to 1180-fold, compared to the overall mean of 
the non-ceria ENM treated rats. These results illustrate the increase and persistence of ceria in 
the liver and spleen due to the ceria ENM infusion. In contrast, brain cerium in ceria ENM-
treated rats ranged from 0.26- to 18-fold of the overall mean of the non-ceria ENM treated rats. 
The apparent distribution of the 30 nm ceria ENM into the brain is consistent with prior finding 
of a commercial ~30 nm ceria ENM in the brain, where it was found in the capillary lumen and 
in some of the adjacent astrocytes 1 and 20 h after its infusion 7.  After a much smaller dose of 
ceria ENM by the oral, intraperitoneal, and iv routes, cerium could not be detected in the brain 
of mice 2. A small percentage of oral and intratracheal doses of ceria ENM was shown by ICP-
MS analysis to be in brain, but techniques, such as electron microscopy, were not utilized to 
determine its location 3. The present and prior results suggest delivery of ceria ENM to the 
brain for therapeutic purposes will require a route of administration other than oral, inhalation, 
or iv; or drug delivery systems that cross the BBB, e.g., via receptor-mediated transport, the 
molecular trojan horse approach 18.  
 
ENMs too large (> 5 nm) to be excreted by the kidney 19, are often retained for prolonged 
periods with little to no decrease in organ concentration 20-27.  We found < 0.5% of the dose of 
the 30 nm ceria used in this report was excreted in the urine and feces within the first 2 weeks 
8. Following intratracheal instillation, nanoceria concentrations in blood, bone, heart, kidney, 
liver, spleen, and testicle generally increased over 28 days, which could be due to continued 
translocation from the lung 3. Blood and heart cerium decreased over 1 week after oral ceria 
ENM gavage but bone, brain, kidney, liver, lung, muscle, spleen, and testicle did not, showing 
no significant clearance from these organs 3. The present findings show ceria, an insoluble 
metal oxide ENM, does not undergo significant clearance from the rat for at least 1 month.  
 
The present results suggest the BBB protects the brain from ceria ENM circulating in the 
blood, and that a large iv dose of these ENMs did not greatly disrupt BBB integrity. The lack of 
brain entry suggests it will be challenging to deliver ceria ENM to the brain. This suggests 
surface coatings that facilitate flux across the BBB or non-traditional routes of drug delivery, 
such as uptake directly into the brain via cranial nerve terminals in the roof of the nasal cavity, 
might be necessary to deliver ceria ENM to the brain. The results suggest unintended 
exposure to ceria ENM should not result in significant brain uptake. The results also inform 
about the fate, up to 1 month, of ceria ENMs that are cleared from the blood; most reside in 
reticuloendothelial organs, where they are retained.  
 
In summary, blood, brain, liver, and spleen cerium were determined 1 and 20 h and 30 days 
after iv infusion of 5, 15, 30, and 55 nm ceria into the rat. Of the 4 sites, ≥ 98% was retained in 
the liver and spleen 20 h after its iv infusion, from which it was not significantly cleared over 30 
days. Intravenous ceria ENM infusion produced modest BBB disruption, as evidenced by 
increased brain fluorescein and horseradish peroxidase, not sufficient to allow appreciable 
brain ceria ENM entry. Electron microscopy revealed only occasional ceria ENM beyond the 
BBB. Nanoceria enters the brain poorly, even in the presence of minor opening of the BBB, 
consistent with studies of other insoluble metal-based ENMs 28. This study was conducted with 
a large ceria ENM dose. The iv infusion of 85 mg/kg, if distributed equally throughout the rat, 
would result in 495,000 nM ceria ENM (as shown in Table 1), which is within the range of ceria 
ENM concentrations employed in some in vitro studies. Given that a large percentage of ceria 
ENM is in mononuclear phagocyte system organs and some organs have much lower ceria 
levels, to as low as nearly zero in brain parenchyma (this study, 2, 8), this large ceria dose 
would be expected to produce concentrations of ceria in some organs similar to those found 
effective in some in vitro studies (Table 1). Given that this work was conducted with single, 
large ceria ENM doses, studies of smaller doses, repeatedly administered, as might better 
model of human exposure to ceria ENM as a therapeutic agent, are warranted. To advance 
ceria ENM as a therapeutic agent, studies of whole animal doses that produce the beneficial 
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Figure legends: 
Figure 1. Primary particle size distribution of the four ceria ENMs determined by TEM. Figure 
1A shows cummulative primary particle size distribution and the best fit log-normal function for 
the ENMs. Figure 1B shows the log-normal differential distribution model for each ENM. 
 
Figure 2. Number- and volume-based particle size distribution of three of the ceria ENMs in 
aqueous supension determined by dynamic light scattering. Representative number-based (left 
panels) and volume-based (right panels) particle size distribution for ceria ENM aqueous 
suspensions. Panels A and B are 5 nm, C and D 15 nm, and E and F 30 nm ceria ENMs. 
 
Figure 3. Percentage of the ceria ENM dose in the blood, brain, spleen, and liver. * Indicates a 
significant difference between treatment (shown) and control conditions (not shown). Bars over 
histograms note a significant difference in the percentage of the ceria dose between the two 
times. 
 
Figure 4.  Ceria ENM localization in liver and spleen after its infusion. The electron microscopic 
image in Panel A illustrates ceria agglomerates (arrows) within two Kupffer cells. Cytoplasmic 
accumulation of nanoceria (arrows) in a spleen cell is shown in the electron microscopic image 
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